Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333200 · ClinicalTrials.gov registry record
Longitudinal Study of Neurodegenerative Disorders
A clinical trial of Tay-Sachs Disease and Krabbe Disease, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT03333200 is a study of Tay-Sachs Disease and Krabbe Disease that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,500 participants, above the 77-participant average among 6 other Tay-Sachs Disease trials with a reported enrollment target (1848% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03333200, a study of Tay-Sachs Disease and Krabbe Disease, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.
Conditions Studied
Interventions
- OTHER Palliative Care
- BIOLOGICAL Hematopoetic Stem Cell Transplantation
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2012-01-11 |
| Est. Completion | 2035-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333200
The ClinicalTrials.gov registry entry for NCT03333200 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 77-participant average among 6 other Tay-Sachs Disease trials with a reported enrollment target (1848% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Tay-Sachs Disease appearing as the primary indexed condition, and to 2 interventions - of which Palliative Care is the first listed.
NCT03333200 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03333200 about?
NCT03333200 is a clinical study titled "Longitudinal Study of Neurodegenerative Disorders". The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.
What is the current status of trial NCT03333200?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2012-01-11. Estimated completion is 2035-01.
What conditions does trial NCT03333200 study?
This clinical trial studies the following conditions: Tay-Sachs Disease, Krabbe Disease, MPS I, Vanishing White Matter Disease, ALD.
What interventions are being tested in trial NCT03333200?
The interventions under investigation include: Palliative Care (OTHER), Hematopoetic Stem Cell Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03333200?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03333200 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tay-Sachs Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Natural History Study of the Gangliosidoses
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff Disease
ACTIVE NOT RECRUITING
-
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
COMPLETED
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
-
Gene Therapy for Tay-Sachs Disease
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.